PMID- 35980912
OWN - NLM
STAT- MEDLINE
DCOM- 20220822
LR  - 20220830
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 17
IP  - 8
DP  - 2022
TI  - Comparison of 8- versus 12-weeks of glecaprevir/pibrentasvir for Taiwanese 
      patients with hepatitis C and compensated cirrhosis in a real-world setting.
PG  - e0272567
LID - 10.1371/journal.pone.0272567 [doi]
LID - e0272567
AB  - Real-world data on the effectiveness of glecaprevir/pibrentasvir (GLE/PIB) for 
      patients with HCV infection and compensated cirrhosis is limited, especially for 
      the 8-week regimen and in an Asian population. This retrospective study enrolled 
      159 consecutive patients with HCV and compensated cirrhosis who were treated with 
      GLE/PIB at a single center in Taiwan. Sustained virological response (SVR) and 
      adverse events (AEs) were evaluated. Among the 159 patients, 91 and 68 were 
      treated with GLE/PIB for 8 and 12 weeks, respectively. In the per protocol 
      analysis, both the 8- and 12-week groups achieved 100% SVR (87/87 vs. 64/64); and 
      in the evaluable population analysis, 95.6% (87/91) of the 8-week group and 94.1% 
      (64/68) of the 12-week group achieved SVR. The most commonly reported AEs, which 
      included pruritus (15.4% vs. 26.5%), abdominal discomfort (9.9% vs. 5.9%), and 
      skin rash (5.5% vs. 5.9%), were mild for the 8- and 12-week groups. Two patients 
      in the 8-week group exhibited total bilirubin elevation over three times the 
      upper normal limit. One of these two patients discontinued GLE/PIB treatment 
      after 2 weeks but still achieved SVR. Both 8- and 12-week GLE/PIB treatments are 
      safe and effective for patients of Taiwanese ethnicity with HCV and compensated 
      cirrhosis.
FAU - Lu, Yung-Hsin
AU  - Lu YH
AD  - Department of Internal Medicine, Division of Gastroenterology and Hepatology, 
      Chang Gung Memorial Hospital, Chiayi, Taiwan.
FAU - Lu, Chung-Kuang
AU  - Lu CK
AD  - Department of Internal Medicine, Division of Gastroenterology and Hepatology, 
      Chang Gung Memorial Hospital, Chiayi, Taiwan.
FAU - Chen, Chun-Hsien
AU  - Chen CH
AD  - Department of Internal Medicine, Division of Gastroenterology and Hepatology, 
      Chang Gung Memorial Hospital, Chiayi, Taiwan.
FAU - Hsieh, Yung-Yu
AU  - Hsieh YY
AD  - Department of Internal Medicine, Division of Gastroenterology and Hepatology, 
      Chang Gung Memorial Hospital, Chiayi, Taiwan.
FAU - Tung, Shui-Yi
AU  - Tung SY
AD  - Department of Internal Medicine, Division of Gastroenterology and Hepatology, 
      Chang Gung Memorial Hospital, Chiayi, Taiwan.
AD  - College of Medicine, Chang Gung University, Taoyuan, Taiwan.
FAU - Chen, Yi-Hsing
AU  - Chen YH
AD  - Department of Internal Medicine, Division of Gastroenterology and Hepatology, 
      Chang Gung Memorial Hospital, Chiayi, Taiwan.
FAU - Yen, Chih-Wei
AU  - Yen CW
AD  - Department of Internal Medicine, Division of Gastroenterology and Hepatology, 
      Chang Gung Memorial Hospital, Chiayi, Taiwan.
FAU - Tung, Wei-Lin
AU  - Tung WL
AD  - Department of Internal Medicine, Division of Gastroenterology and Hepatology, 
      Chang Gung Memorial Hospital, Chiayi, Taiwan.
FAU - Chang, Kao-Chi
AU  - Chang KC
AD  - Department of Internal Medicine, Division of Gastroenterology and Hepatology, 
      Chang Gung Memorial Hospital, Chiayi, Taiwan.
FAU - Chen, Wei-Ming
AU  - Chen WM
AUID- ORCID: 0000-0002-4949-393X
AD  - Department of Internal Medicine, Division of Gastroenterology and Hepatology, 
      Chang Gung Memorial Hospital, Chiayi, Taiwan.
FAU - Lu, Sheng-Nan
AU  - Lu SN
AD  - Department of Internal Medicine, Division of Gastroenterology and Hepatology, 
      Chang Gung Memorial Hospital, Chiayi, Taiwan.
AD  - College of Medicine, Chang Gung University, Taoyuan, Taiwan.
FAU - Hung, Chao-Hung
AU  - Hung CH
AD  - Department of Internal Medicine, Division of Gastroenterology and Hepatology, 
      Chang Gung Memorial Hospital, Chiayi, Taiwan.
AD  - College of Medicine, Chang Gung University, Taoyuan, Taiwan.
FAU - Chang, Te-Sheng
AU  - Chang TS
AUID- ORCID: 0000-0002-1581-6948
AD  - Department of Internal Medicine, Division of Gastroenterology and Hepatology, 
      Chang Gung Memorial Hospital, Chiayi, Taiwan.
AD  - College of Medicine, Chang Gung University, Taoyuan, Taiwan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220818
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Aminoisobutyric Acids)
RN  - 0 (Antiviral Agents)
RN  - 0 (Benzimidazoles)
RN  - 0 (Cyclopropanes)
RN  - 0 (Lactams, Macrocyclic)
RN  - 0 (Pyrrolidines)
RN  - 0 (Quinoxalines)
RN  - 0 (Sulfonamides)
RN  - 2WU922TK3L (pibrentasvir)
RN  - 9DLQ4CIU6V (Proline)
RN  - GMW67QNF9C (Leucine)
RN  - K6BUU8J72P (glecaprevir)
SB  - IM
MH  - Aminoisobutyric Acids
MH  - Antiviral Agents/adverse effects
MH  - Benzimidazoles
MH  - Cyclopropanes
MH  - Hepacivirus
MH  - *Hepatitis C/chemically induced/complications/drug therapy
MH  - *Hepatitis C, Chronic/complications/drug therapy/epidemiology
MH  - Humans
MH  - Lactams, Macrocyclic
MH  - Leucine/analogs & derivatives
MH  - Liver Cirrhosis/chemically induced/complications/drug therapy
MH  - Proline/analogs & derivatives/therapeutic use
MH  - Pyrrolidines/therapeutic use
MH  - Quinoxalines/adverse effects
MH  - Retrospective Studies
MH  - Sulfonamides
PMC - PMC9387785
COIS- The authors have declared that no competing interests exist.
EDAT- 2022/08/19 06:00
MHDA- 2022/08/23 06:00
PMCR- 2022/08/18
CRDT- 2022/08/18 13:44
PHST- 2022/05/28 00:00 [received]
PHST- 2022/07/22 00:00 [accepted]
PHST- 2022/08/18 13:44 [entrez]
PHST- 2022/08/19 06:00 [pubmed]
PHST- 2022/08/23 06:00 [medline]
PHST- 2022/08/18 00:00 [pmc-release]
AID - PONE-D-22-15455 [pii]
AID - 10.1371/journal.pone.0272567 [doi]
PST - epublish
SO  - PLoS One. 2022 Aug 18;17(8):e0272567. doi: 10.1371/journal.pone.0272567. 
      eCollection 2022.